The GLP-1 agonist albiglutide reduces major CV events by 20% in type 2 diabetes patients with cardiovascular disease; GSK has ceased marketing the drug but say they will seek a new home for it.

HealthDay News — For patients with type 2 diabetes and existing cardiovascular disease, albiglutide results in fewer cardiovascular events, according to a study published online October 2 in The ...

Patients with type 2 diabetes that is not controlled with first-line therapy had fewer gastrointestinal adverse effects with albiglutide, but it was not superior to liraglutide.

Albiglutide (trade name Eperzan) has been approved since March 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. The German ...

Albiglutide therapy as an adjunct to standard type 2 diabetes treatment reduced cardiovascular event incidence among older adults.

Data from five long-term Phase III studies (Harmony 1 to 5) comparing albiglutide, an investigational glucagon-like peptide receptor agonist (GLP-1), to placebo and a range of active comparators ...

GlaxoSmithKline PLC's diabetes treatment albiglutide was approved for use by U.S. regulators, after a series of drug-development setbacks for the company.

Albiglutide (TanzeumTM/Eperzan®) is a glucagon-like peptide-1 receptor agonist (GLP-1), a biological product for the treatment of type 2 diabetes, administered once-weekly using an injector pen ...

For the albiglutide meta-analysis, an independent clinical endpoints committee adjudicated cardiovascular events across all eight Phase 3 Harmony studies and from one Phase 2 study.

Eperzan (albiglutide) receives EMA approval | Regulatory NewsVlad Hogenhuis, Senior Vice-President and Head, GSK Global Cardiovascular, Metabolic and Neurosciences (CVM&NS) Franchise, said ...

Albiglutide (trade name Eperzan) has been approved since March 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. The German ...